Skip to Content

BexxarTherapeutic Side Effects

Generic Name: tositumomab

Note: This document contains side effect information about tositumomab. Some of the dosage forms listed on this page may not apply to the brand name BexxarTherapeutic.

Applies to tositumomab: intravenous kit

Cardiovascular

Common (1% to 10%): Hypotension, vasodilation[Ref]

Dermatologic

Very common (10% or more): Rash, pruritus
Common (1% to 10%): Sweating[Ref]

Endocrine

Common (1% to 10%): Hypothyroidism[Ref]

Gastrointestinal

Very common (10% or more): Abdominal pain, nausea, vomiting, diarrhea, anorexia
Common (1% to 10%): Constipation, dyspepsia[Ref]

Hematologic

Very common (10% or more): Neutropenia, thrombocytopenia, anemia[Ref]

Hypersensitivity

Common (1% to 10%): Allergic (hypersensitivity) reactions (allergic reaction, facial edema, injection site hypersensitivity, anaphylactic reaction, laryngismus, serum sickness)
Postmarketing reports: Hypersensitivity reactions including fatal anaphylaxis[Ref]

Immunologic

Very common (10% or more): Positive serology for human anti-mouse antibodies (HAMA)[Ref]

Local

Frequency not reported: Infusion reactions[Ref]

Metabolic

Common (1% to 10%): Peripheral edema, weight loss[Ref]

Musculoskeletal

Very common (10% or more): Myalgia, arthralgia
Common (1% to 10%): Back pain, neck pain[Ref]

Nervous system

Common (1% to 10%): Dizziness, somnolence
Postmarketing reports: Axonal neuropathy leading to quadriparesis[Ref]

Oncologic

Common (1% to 10%): Secondary malignancies (non-melanoma skin, colorectal, head and neck, breast, lung, bladder, melanoma, gastric)
Frequency not reported: Secondary leukemia, myelodysplastic syndrome[Ref]

Other

Very common (10% or more): Asthenia, fever, infections, pain, chills, headache
Common (1% to 10%): Chest pain, serious infections (pneumonia, bacteremia, septicemia, bronchitis, skin infections)[Ref]

Respiratory

Very common (10% or more): Cough, pharyngitis, dyspnea, rhinitis
Common (1% to 10%): Pneumonia[Ref]

References

1. "Product Information. Bexxar I 131 Therapeutic (iodine I 131 tositumomab)." GlaxoSmithKline, Research Triangle Park, NC.

2. "Product Information. BexxarTherapy (tositumomab)." GlaxoSmithKline Inc, Oakville, IA.

Some side effects of BexxarTherapeutic may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide